-
1
-
-
0000734220
-
Malignant neoplasms of the liver
-
Schiff ER, Sorrel MF, Maddrey WC, 8th ed. Philadelphia: Lippincott-Raven Publishers
-
Di Bisceglie AM. Malignant neoplasms of the liver. In: Schiff ER, Sorrel MF, Maddrey WC. Schiff's disease of the liver. 8th ed. Vol. 2. Philadelphia: Lippincott-Raven Publishers: 1999, pp. 1281-1304.
-
(1999)
Schiff's disease of the liver
, vol.2
, pp. 1281-1304
-
-
Di Bisceglie, A.M.1
-
2
-
-
0001605891
-
Hepatic tumors and cysts
-
Feldman M, Sleisenger MH, Scharschmidt BF, 6th ed. Philadelphia: WB Saunders;
-
Kew MC. Hepatic tumors and cysts. In: Feldman M, Sleisenger MH, Scharschmidt BF. Gastrointestinal and liver disease. 6th ed. Philadelphia: WB Saunders; 1998, pp. 1364-1387.
-
(1998)
Gastrointestinal and liver disease
, pp. 1364-1387
-
-
Kew, M.C.1
-
3
-
-
0033545541
-
Rising incidence of hepatocellular carcinoma in the United States
-
El-Serag HB, Mason A. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340:745-750.
-
(1999)
N Engl J Med
, vol.340
, pp. 745-750
-
-
El-Serag, H.B.1
Mason, A.2
-
4
-
-
0035200712
-
Trends in survival of patienls with hepatocellular carcinoma between 1997 and 1996 in the United States
-
El-Serag HB, Mason A, Key C. Trends in survival of patienls with hepatocellular carcinoma between 1997 and 1996 in the United States. Hepatology 2001; 33:62-65.
-
(2001)
Hepatology
, vol.33
, pp. 62-65
-
-
El-Serag, H.B.1
Mason, A.2
Key, C.3
-
5
-
-
0033590207
-
The role of cyclooxygenase in inflammation, cancer and development
-
Willams CS, Mann M, DuBois RN. The role of cyclooxygenase in inflammation, cancer and development. Oncology 1999; 18:7908-7916.
-
(1999)
Oncology
, vol.18
, pp. 7908-7916
-
-
Willams, C.S.1
Mann, M.2
DuBois, R.N.3
-
6
-
-
0036014815
-
Rationale and feasibility of chemoprevention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors
-
Hu K-Q. Rationale and feasibility of chemoprevention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med 2002; 139: 234-243.
-
(2002)
J Lab Clin Med
, vol.139
, pp. 234-243
-
-
Hu, K.-Q.1
-
7
-
-
0034471496
-
Biochemistry of cyclooxygenase (COX-2) inhibitors and molecular pathology of COX-2 in neoplasia
-
Fosslien E. Biochemistry of cyclooxygenase (COX-2) inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000; 37:431-502.
-
(2000)
Crit Rev Clin Lab Sci
, vol.37
, pp. 431-502
-
-
Fosslien, E.1
-
8
-
-
0042198296
-
Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor
-
Hu K-Q, Yu C-H, Mineyama Y, McCrachen JD, Hillebrand DJ, Hasan M. Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor. Int J Oncol 2003; 22: 757-763.
-
(2003)
Int J Oncol
, vol.22
, pp. 757-763
-
-
Hu, K.-Q.1
Yu, C.-H.2
Mineyama, Y.3
McCrachen, J.D.4
Hillebrand, D.J.5
Hasan, M.6
-
9
-
-
0034905269
-
Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398
-
Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim DG, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 2001; 7:1410-1418.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 1410-1418
-
-
Bae, S.H.1
Jung, E.S.2
Park, Y.M.3
Kim, B.S.4
Kim, B.K.5
Kim, D.G.6
-
10
-
-
0036788542
-
Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells
-
Kern MA, Schubert D, Sahi D, Schöneweiss MM, Moll I, Haugg AM, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002; 36:885-894.
-
(2002)
Hepatology
, vol.36
, pp. 885-894
-
-
Kern, M.A.1
Schubert, D.2
Sahi, D.3
Schöneweiss, M.M.4
Moll, I.5
Haugg, A.M.6
-
11
-
-
0344275593
-
Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells
-
Cheng ASL, Chan HY, Leung W, Wong N, Johnson PJ, Sung JY. Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells. Int J Oncol 2003; 23:113-119.
-
(2003)
Int J Oncol
, vol.23
, pp. 113-119
-
-
Cheng, A.S.L.1
Chan, H.Y.2
Leung, W.3
Wong, N.4
Johnson, P.J.5
Sung, J.Y.6
-
12
-
-
3242809061
-
Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice
-
Kern MA, Schöneweiss MM, Sahi D, Bahlo M, Haugg AM, Kasper HU, et al. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis 2004; 25:1193-1199.
-
(2004)
Carcinogenesis
, vol.25
, pp. 1193-1199
-
-
Kern, M.A.1
Schöneweiss, M.M.2
Sahi, D.3
Bahlo, M.4
Haugg, A.M.5
Kasper, H.U.6
-
13
-
-
0041822007
-
Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through AKT activation: Evidence for AKT inhibition in celecoxib-induced apoptosis
-
Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through AKT activation: evidence for AKT inhibition in celecoxib-induced apoptosis. Hepatology 2003; 38:756-768.
-
(2003)
Hepatology
, vol.38
, pp. 756-768
-
-
Leng, J.1
Han, C.2
Demetris, A.J.3
Michalopoulos, G.K.4
Wu, T.5
-
14
-
-
28144445331
-
In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human HCC cells
-
Cui W, Yu CH, Hu KQ. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human HCC cells. Clin Cancer Res 2005; 11:8213-8221.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 8213-8221
-
-
Cui, W.1
Yu, C.H.2
Hu, K.Q.3
-
15
-
-
52649107877
-
In vivo effects of cyclooxygenase-2 deletion on cellular signaling in hepatocellular carcinoma xenografts in nude mice
-
Cui W, Hu SX, Tang ZY, Hu KQ. In vivo effects of cyclooxygenase-2 deletion on cellular signaling in hepatocellular carcinoma xenografts in nude mice. J Cancer Mol 2007; 3:49-54.
-
(2007)
J Cancer Mol
, vol.3
, pp. 49-54
-
-
Cui, W.1
Hu, S.X.2
Tang, Z.Y.3
Hu, K.Q.4
-
16
-
-
18344368896
-
Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and NSAIDs: A population-based case-control study
-
Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and NSAIDs: a population-based case-control study. Arch Intern Med 2005; 165:978-984.
-
(2005)
Arch Intern Med
, vol.165
, pp. 978-984
-
-
Johnsen, S.P.1
Larsson, H.2
Tarone, R.E.3
McLaughlin, J.K.4
Nørgård, B.5
Friis, S.6
-
17
-
-
0035143887
-
The role of serum alpha-fetoprote in estimation in the diagnosis and management of hepatocellular carcinoma
-
Johnson PJ. The role of serum alpha-fetoprote in estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 145-159.
-
(2001)
Clin Liver Dis
, vol.5
, pp. 145-159
-
-
Johnson, P.J.1
-
18
-
-
0031017944
-
Significance of alpha-fetoprotein levels for detection of early recurrence of hepatocellular carcinoma after hepatic resection
-
Shirabe K, Takenaka K, Gion T, Shimada M, Fujiwara Y, Sugimachi K. Significance of alpha-fetoprotein levels for detection of early recurrence of hepatocellular carcinoma after hepatic resection. J Surg Oncol 1997; 64:143-146.
-
(1997)
J Surg Oncol
, vol.64
, pp. 143-146
-
-
Shirabe, K.1
Takenaka, K.2
Gion, T.3
Shimada, M.4
Fujiwara, Y.5
Sugimachi, K.6
-
19
-
-
4544301860
-
High α-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: Significance of hepatitis virus infection, age, p53 and β-catenin mutations
-
Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High α-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and β-catenin mutations. Int J Cancer 2004; 112:44-50.
-
(2004)
Int J Cancer
, vol.112
, pp. 44-50
-
-
Peng, S.Y.1
Chen, W.J.2
Lai, P.L.3
Jeng, Y.M.4
Sheu, J.C.5
Hsu, H.C.6
-
20
-
-
13844273087
-
PI3K-Akt pathway: Its function and alterations in human cancer
-
Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its function and alterations in human cancer. Apoptosis 2004; 9:667-676.
-
(2004)
Apoptosis
, vol.9
, pp. 667-676
-
-
Osaki, M.1
Oshimura, M.2
Ito, H.3
-
21
-
-
0034845958
-
PKB/Akt: A key mediator of cell proliferation, survival and insulin responses?
-
Lawlor Ma, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001; 114:2903-2910.
-
(2001)
J Cell Sci
, vol.114
, pp. 2903-2910
-
-
Ma, L.1
Alessi, D.R.2
-
22
-
-
0028963084
-
Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor
-
Yao R, Cooper GM. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 1995; 267: 2003-2006.
-
(1995)
Science
, vol.267
, pp. 2003-2006
-
-
Yao, R.1
Cooper, G.M.2
-
23
-
-
0030936323
-
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
-
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-1947.
-
(1997)
Science
, vol.275
, pp. 1943-1947
-
-
Li, J.1
Yen, C.2
Liaw, D.3
Podsypanina, K.4
Bose, S.5
Wang, S.I.6
-
24
-
-
17144436629
-
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
-
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15:356-362.
-
(1997)
Nat Genet
, vol.15
, pp. 356-362
-
-
Steck, P.A.1
Pershouse, M.A.2
Jasser, S.A.3
Yung, W.K.4
Lin, H.5
Ligon, A.H.6
-
25
-
-
17844368327
-
The MAPK signaling pathways and colorectal cancer
-
Fang JY, Richardson BC. The MAPK signaling pathways and colorectal cancer. Lancet Oncol 2005; 6:322-327.
-
(2005)
Lancet Oncol
, vol.6
, pp. 322-327
-
-
Fang, J.Y.1
Richardson, B.C.2
-
26
-
-
19644388719
-
Pharmacologic inhibition of RAF/ MEK/ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kipi
-
Gysin S, Lee SH, Dean NM, McMahon M. Pharmacologic inhibition of RAF/ MEK/ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kipi. Cancer Res 2005; 65:4870-4880.
-
(2005)
Cancer Res
, vol.65
, pp. 4870-4880
-
-
Gysin, S.1
Lee, S.H.2
Dean, N.M.3
McMahon, M.4
-
27
-
-
1442335098
-
Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma
-
Wiesenauer CA, Yip-Schneider MT, Wang Y, Schmidt CM. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. J Am Coll Surg 2004; 198:410-421.
-
(2004)
J Am Coll Surg
, vol.198
, pp. 410-421
-
-
Wiesenauer, C.A.1
Yip-Schneider, M.T.2
Wang, Y.3
Schmidt, C.M.4
-
29
-
-
33645950778
-
Histone deacetylase inhibitors: Multifunctional anticancer agents
-
Liu T, Kuljaca S, Tee A, Marshal GM. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 2006; 32:157-165.
-
(2006)
Cancer Treat Rev
, vol.32
, pp. 157-165
-
-
Liu, T.1
Kuljaca, S.2
Tee, A.3
Marshal, G.M.4
-
30
-
-
0035063182
-
Transcriptional control at regulatory checkpoints by histone deacetylase: Molecular connections between cancer and chromatin
-
Wade PA. Transcriptional control at regulatory checkpoints by histone deacetylase: molecular connections between cancer and chromatin. Hum Mol Genet 2001; 10:693-698.
-
(2001)
Hum Mol Genet
, vol.10
, pp. 693-698
-
-
Wade, P.A.1
-
31
-
-
0034045040
-
Histone deacetylases, transcriptional control, and cancer
-
Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2002; 184:1-16.
-
(2002)
J Cell Physiol
, vol.184
, pp. 1-16
-
-
Cress, W.D.1
Seto, E.2
-
32
-
-
21044447215
-
Increased expression of histone deacetylase 2 is found in human gastric cancer
-
Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY, et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005; 113:264-268.
-
(2005)
APMIS
, vol.113
, pp. 264-268
-
-
Song, J.1
Noh, J.H.2
Lee, J.H.3
Eun, J.W.4
Ahn, Y.M.5
Kim, S.Y.6
-
33
-
-
4143093730
-
Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: A mechanism for the functional loss of PTEN's tumor suppressor activity
-
Meuillet EJ, Mahadevan D, Berggren M, Coon A, Powis G. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Arch Biochem Biophys 2004; 429:123-133.
-
(2004)
Arch Biochem Biophys
, vol.429
, pp. 123-133
-
-
Meuillet, E.J.1
Mahadevan, D.2
Berggren, M.3
Coon, A.4
Powis, G.5
-
34
-
-
0036279847
-
Celecoxib, a cycloxygenase-2 inhibitor as a potential chemopreventive to UV-induced skin cancer
-
Orengo IF, Gergois J, Phillpis R, Guevara A, Lewis AT, Black HS. Celecoxib, a cycloxygenase-2 inhibitor as a potential chemopreventive to UV-induced skin cancer. Arch Dermatol 2002; 138:751-755.
-
(2002)
Arch Dermatol
, vol.138
, pp. 751-755
-
-
Orengo, I.F.1
Gergois, J.2
Phillpis, R.3
Guevara, A.4
Lewis, A.T.5
Black, H.S.6
-
35
-
-
0038389867
-
PPARγ pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells
-
Li MY, Deng H, Zhao JM, Dai D, Tan XY. PPARγ pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells. World J Gastroenterol 2003; 9:1220-1225.
-
(2003)
World J Gastroenterol
, vol.9
, pp. 1220-1225
-
-
Li, M.Y.1
Deng, H.2
Zhao, J.M.3
Dai, D.4
Tan, X.Y.5
-
36
-
-
0036278855
-
A ligand for peroxisome proliferator activated receptor γ inhibits cell growth and induces apoptosis in human liver cancer cells
-
Toyoda M, Takagi H, Horiguchi N, Kakizaki S, Sato K, Takayama H, et al. A ligand for peroxisome proliferator activated receptor γ inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 2002; 50:563-567.
-
(2002)
Gut
, vol.50
, pp. 563-567
-
-
Toyoda, M.1
Takagi, H.2
Horiguchi, N.3
Kakizaki, S.4
Sato, K.5
Takayama, H.6
-
37
-
-
0036839817
-
Peroxisome proliferator-activated receptor-γ is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth
-
Wick M, Hurteau G, Dessev C, Chan D, Geraci MW, Winn RA, et al. Peroxisome proliferator-activated receptor-γ is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol 2002; 62:1207-1214.
-
(2002)
Mol Pharmacol
, vol.62
, pp. 1207-1214
-
-
Wick, M.1
Hurteau, G.2
Dessev, C.3
Chan, D.4
Geraci, M.W.5
Winn, R.A.6
-
38
-
-
0031013395
-
Peroxisome proliferatorsactivated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs
-
Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferatorsactivated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272:3406-3410.
-
(1997)
J Biol Chem
, vol.272
, pp. 3406-3410
-
-
Lehmann, J.M.1
Lenhard, J.M.2
Oliver, B.B.3
Ringold, G.M.4
Kliewer, S.A.5
-
39
-
-
0036195196
-
AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis
-
Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT, et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002; 23:201-205.
-
(2002)
Carcinogenesis
, vol.23
, pp. 201-205
-
-
Roy, H.K.1
Olusola, B.F.2
Clemens, D.L.3
Karolski, W.J.4
Ratashak, A.5
Lynch, H.T.6
-
40
-
-
2442689399
-
Serine/threonone kinase AKT is frequently activated in human bile duct cancer and is associated with increased radioresistance
-
Altomare DA, Tanno S, De Rienzo A, Klein-Szanto AJ, Tanno S, Skele KL, et al. Serine/threonone kinase AKT is frequently activated in human bile duct cancer and is associated with increased radioresistance. Cancer Res 2004; 64:3486-3490.
-
(2004)
Cancer Res
, vol.64
, pp. 3486-3490
-
-
Altomare, D.A.1
Tanno, S.2
De Rienzo, A.3
Klein-Szanto, A.J.4
Tanno, S.5
Skele, K.L.6
-
41
-
-
0036632368
-
The phosphatidylinositol 3-kinase AKT pathway in human cancer
-
Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 489-501
-
-
Vivanco, I.1
Sawyers, C.L.2
-
42
-
-
0035949699
-
AKT plays a central role in tumorigenesis
-
Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 2001; 98:10983-10985.
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, pp. 10983-10985
-
-
Testa, J.R.1
Bellacosa, A.2
-
43
-
-
0027283659
-
-
Lenormand P, Sardet C, Pages G, L'Allemain G, Brunet A, Pouyssegur J. Growth factors induce nuclear translocation of MAP kinase (p42 mapk and p44 mapk) but not of their activator MAPK kinase kinase (p45 mapk) in fibroblasts. J Cell Biol 1993; 122:1079-1088.
-
Lenormand P, Sardet C, Pages G, L'Allemain G, Brunet A, Pouyssegur J. Growth factors induce nuclear translocation of MAP kinase (p42 mapk and p44 mapk) but not of their activator MAPK kinase kinase (p45 mapk) in fibroblasts. J Cell Biol 1993; 122:1079-1088.
-
-
-
|